Dose Ranging Study With the Probiotic Combination (VSL#3) in Diarrhea IBS

Beth Israel Deaconess Medical Center180 enrolled

Overview

To evaluate the effects of VSL#3 on symptoms associated with diarrhea predominant IBS

The study will evaluate 2 doses of VSL#3 and placebo over a 4 week period in patients presenting with diarrhea predominant IBS symptoms.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

180

Conditions

IBS

Interventions

VSL#3DRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * IBS diarrhea Exclusion Criteria: * \< 18 years of age * Pregnancy/breast feeding * concomitant medications to reduce bowel function

Locations (1)

BIDMC

Boston, Massachusetts, United States

Outcomes

Primary Outcomes

Global improvement in IBS symptoms

Secondary Outcomes

Frequency of bowel movements

Changes in abdominal pain

Changes in bloating

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.